Trifluoromethanesulfonic Acid

Trifluoromethanesulfonic Acid

SCHEMBL3971065

Cc1cc(Nc2cc3cc(O)ccc3c(-c3ccc(F)cc3F)n2)n[nH]1.O=S(=O)(O)C(F)(F)F

nearest known ligand 0.39

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 10/20 0.39
NTRK3 Q16288 3/20 0.39
NTRK2 Q16620 3/20 0.39
AURKA O14965 1/20 0.38
AURKB Q96GD4 1/20 0.38
NPC1 O15118 1/20 0.37
TP53 P04637 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2C19 P33261 1/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
SYK P43405 3/20 0.36
PLK4 O00444 2/20 0.36
PAK4 O96013 2/20 0.36
DHODH Q02127 1/20 0.35
JAK2 O60674 1/20 0.35
JAK3 P52333 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3964062 0.92 NTRK1 (0.45) NTRK1NTRK3NTRK2AURKAAURKB
SCHEMBL3967278 0.84 PIK3C3 (0.40) NTRK1NTRK3NTRK2AURKAAURKB
SCHEMBL3972203 0.81 AURKA (0.45) NTRK1NTRK3NTRK2AURKAAURKB
SCHEMBL3969451 0.79 NTRK1 (0.50) NTRK1NTRK3NTRK2AURKAAURKB
SCHEMBL3968575 0.78 AURKA (0.46) NTRK1NTRK3NTRK2AURKAAURKB
SCHEMBL3968846 0.75 AURKA (0.42) NTRK1NTRK3NTRK2AURKAAURKB
SCHEMBL3968585 0.74 SYK (0.46) NTRK1NTRK3NTRK2AURKAAURKB
SCHEMBL3967347 0.74 PAK4 (0.47) NTRK1AURKAAURKBRAB9APAK4
SCHEMBL13716663 0.73 KDM4E (0.42) NTRK1NPC1TP53CYP1A2CYP2C19
SCHEMBL3963984 0.72 AURKA (0.44) NTRK1NTRK3NTRK2AURKAAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7572809-B2 Isoquinoline aminopyrazole derivatives HOFFMANN-LA ROCHE INC. (US) 2009-08-11 US disclosed
EP-1966190-A1 ISOQUINOLINE AMINOPYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CANCER F.HOFFMANN-LA ROCHE AG (CH) 2008-09-10 EP disclosed
US-20070179151-A1 Isoquinoline aminopyrazole derivatives F. HOFMANN-LA ROCHE AG (CH) 2007-08-02 US disclosed
WO-2007071348-A1 ISOQUINOLINE AMINOPYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2007-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179151-A1 Isoquinoline aminopyrazole derivatives CYP3A5, CYP3A43, CYP3A4 NTRK1 4316/4885NTRK3 3828/4885NTRK2 4162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.